Japan’s Gunma University Hospital is planning what is roughly positioned as a mid-stage clinical trial covering hydroxychloroquine and other medicines for the novel virus disease.
According to the university, it is planning to conduct “specified clinical research” (tokutei rinsho kenkyu; clinical research on unapproved drugs/indications or clinical research funded by drug maker) on multiple drugs including the Sanofi immune modulator, otherwise known as Plaquenil. “The program aims to explore appropriate dosages and administration periods, and I’d say roughly PII if it was a clinical trial,” a university official told Jiho.
Asked about this trial, Shigeyuki Kano, president of the Japanese Society of Tropical Medicine, who is advocating a clinical trial to test the drug for the prevention of COVID-19, told Jiho, “We are hoping to see balanced evidence coming out of the NIH trial this time on its therapeutic efficacy and side effect risks.” “Cases showing its efficacy in COVID-19 are accumulating through observational research,” he also said.
Read the original article here: https://pj.jiho.jp/article/